These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 25573948

  • 1. Guideline-Concordant Treatment of Kawasaki Disease With Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm.
    Michihata N, Matsui H, Fushimi K, Yasunaga H.
    Clin Pediatr (Phila); 2015 Oct; 54(11):1076-80. PubMed ID: 25573948
    [Abstract] [Full Text] [Related]

  • 2. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC, Aronoff SC.
    Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
    [Abstract] [Full Text] [Related]

  • 3. [Kawasaki disease in children--9 years experience].
    Kowalczyk M, Kawalec W, Daszkowska-York J, Turska-Kmieć A, Brzezińska-Rajszys G, Sobielarska D, Ziółkowska L, Kościesza A, Jagiełłowicz D, Mirecka-Rola A.
    Med Wieku Rozwoj; 2005 Oct; 9(2):179-93. PubMed ID: 16085959
    [Abstract] [Full Text] [Related]

  • 4. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
    Durongpisitkul K, Sangtawesin C, Khongphatthanayopthin A, Panamonta M, Sopontammarak S, Sittiwangkul R, Pongpanich B.
    Asian Pac J Allergy Immunol; 2006 Mar; 24(1):27-32. PubMed ID: 16913186
    [Abstract] [Full Text] [Related]

  • 5. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC.
    Lancet; 2014 May 17; 383(9930):1731-8. PubMed ID: 24572997
    [Abstract] [Full Text] [Related]

  • 6. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J, Chen H, Shi H, Zhang X, Shao Y, Hang B, Xu Z, Rong X, Chu M, Qiu H.
    Pediatr Rheumatol Online J; 2020 Jun 11; 18(1):48. PubMed ID: 32527316
    [Abstract] [Full Text] [Related]

  • 7. Infections and Kawasaki disease: implications for coronary artery outcome.
    Benseler SM, McCrindle BW, Silverman ED, Tyrrell PN, Wong J, Yeung RS.
    Pediatrics; 2005 Dec 11; 116(6):e760-6. PubMed ID: 16322132
    [Abstract] [Full Text] [Related]

  • 8. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
    Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM.
    Pediatrics; 2004 Dec 11; 114(6):e689-93. PubMed ID: 15545617
    [Abstract] [Full Text] [Related]

  • 9. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B, Belarski E, Manaloor J, Ofner S, Carroll AE, John CC, Wood JB.
    JAMA Netw Open; 2020 Jan 03; 3(1):e1918565. PubMed ID: 31899532
    [Abstract] [Full Text] [Related]

  • 10. Kawasaki disease patients with six principal symptoms have a high risk of being a non-responder.
    Nomura Y, Arata M, Masuda K, Koriyama C, Suruki N, Ueno K, Yoshikawa H, Eguchi T, Kawano Y.
    Pediatr Int; 2012 Feb 03; 54(1):14-8. PubMed ID: 22115193
    [Abstract] [Full Text] [Related]

  • 11. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH.
    PLoS One; 2015 Feb 03; 10(12):e0144603. PubMed ID: 26658843
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 03; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 13. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y.
    Arch Dis Child; 2008 Feb 03; 93(2):142-6. PubMed ID: 17962370
    [Abstract] [Full Text] [Related]

  • 14. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease.
    Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED.
    Pediatr Cardiol; 2003 Feb 03; 24(2):122-6. PubMed ID: 12457252
    [Abstract] [Full Text] [Related]

  • 15. [Six Kawasaki disease patients with acute coronary artery thrombosis].
    Zhou SL, Luo JP, Qi YQ, Liang YG, Wang W, Gong FQ.
    Zhonghua Er Ke Za Zhi; 2013 Dec 03; 51(12):925-9. PubMed ID: 24495764
    [Abstract] [Full Text] [Related]

  • 16. Kawasaki shock syndrome presenting as toxic shock syndrome.
    Saha A, Khalil S, Kapoor K, Gupta A, Dubey NK.
    Int J Rheum Dis; 2013 Aug 03; 16(4):480-2. PubMed ID: 23992273
    [No Abstract] [Full Text] [Related]

  • 17. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome.
    Baer AZ, Rubin LG, Shapiro CA, Sood SK, Rajan S, Shapir Y, Romano A, Bierman FZ.
    Arch Pediatr Adolesc Med; 2006 Jul 03; 160(7):686-90. PubMed ID: 16818833
    [Abstract] [Full Text] [Related]

  • 18. High-dose aspirin for Kawasaki disease: outdated myth or effective aid?
    Amarilyo G, Koren Y, Brik Simon D, Bar-Meir M, Bahat H, Helou MH, Mendelson A, Hezkelo N, Chodick G, Berkun Y, Eisenstein E, Butbul Aviel Y, Barkai G, Bolkier Y, Padeh S, Brik R, Hashkes PJ, Harel L, Uziel Y.
    Clin Exp Rheumatol; 2017 Jul 03; 35 Suppl 103(1):209-212. PubMed ID: 28079513
    [Abstract] [Full Text] [Related]

  • 19. [The role of immunosuppressive agents in Kawasaki disease: a discussion of two cases].
    Peyre M, Laroche C, Etchecopar C, Brosset P.
    Arch Pediatr; 2013 Jul 03; 20(7):748-53. PubMed ID: 23693156
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
    Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators.
    Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.